Antioxidant PDA-PEG Nanoparticles Alleviate Early Osteoarthritis by Inhibiting Osteoclastogenesis and Angiogenesis in Subchondral Bone

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2022 Nov 17

PMID 36384720

Authors

Zhikai Wu

Kai Yuan

Qian Zhang

Jiong Jiong Guo

Huilin Yang

Feng Zhou

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence suggests that osteoclastogenesis and angiogenesis in subchondral bone are critical destructive factors in the initiation and progression of osteoarthritis (OA). Herein, methoxypolyethylene glycol amine (mPEG-NH) modified polydopamine nanoparticles (PDA-PEG NPs) were synthesized for treating early OA. The cytotoxicity and reactive oxygen species (ROS) scavenging ability of PDA-PEG NPs were evaluated. The effects of PDA-PEG NPs on osteoclast differentiation and vessel formation were then evaluated. Further, PDA-PEG NPs were administrated to anterior cruciate ligament transection (ACLT)-induced OA mice. Results demonstrated that PDA-PEG NPs had low toxicity both in vitro and in vivo. PDA-PEG NPs could inhibit osteoclastogenesis via regulating nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways. Moreover, PDA-PEG NPs suppressed osteoclast-related angiogenesis via down-regulating platelet-derived growth factor-BB (PDGF-BB). In vivo, PDA-PEG NPs inhibited subchondral bone resorption and angiogenesis, further rescuing cartilage degradation in OA mice. In conclusion, we demonstrated that PDA-PEG NPs deployment could be a potential therapy for OA.

Citing Articles

Preclinical pharmaco-toxicological screening of biomimetic melanin-like nanoparticles as a potential therapeutic strategy for cutaneous melanoma.

Marcovici I, Chioibas R, Zupko I, Pinzaru I, Moaca A, Ledeti A Front Pharmacol. 2025; 16:1487854.

PMID: 39981176 PMC: 11839674. DOI: 10.3389/fphar.2025.1487854.

Systematic Review of Interleukin-35 in Endothelial Dysfunction: A New Target for Therapeutic Intervention.

Li K, Feng J, Li M, Han L, Wu Y Mediators Inflamm. 2025; 2025:2003124.

PMID: 39974277 PMC: 11839265. DOI: 10.1155/mi/2003124.

Metal ion-crosslinking multifunctional hydrogel microspheres with inflammatory immune regulation for cartilage regeneration.

Xu Z, Ma J, Hu H, Liu J, Yang H, Chen J Front Bioeng Biotechnol. 2025; 13:1540592.

PMID: 39935604 PMC: 11810939. DOI: 10.3389/fbioe.2025.1540592.

Custom-Made Ce-Mn Bimetallic Nanozyme for the Treatment of Intervertebral Disc Degeneration by Inhibiting Oxidative Stress and Modulating Macrophage M1/M2 Polarization.

Wu J, Chen Z, Huang H, Wang H, Wang X, Lu Z Biomater Res. 2024; 28:0118.

PMID: 39717477 PMC: 11665849. DOI: 10.34133/bmr.0118.

Investigating Angiogenesis-Related Biomarkers in Osteoarthritis Patients Through Transcriptomic Profiling.

Zheng Y, Fang M, Sanan S, Meng X, Huang J, Qian Y J Inflamm Res. 2024; 17:10681-10697.

PMID: 39677287 PMC: 11638479. DOI: 10.2147/JIR.S493889.

References

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Zhu T, Cui Y, Zhang M, Zhao D, Liu G, Ding J . Engineered three-dimensional scaffolds for enhanced bone regeneration in osteonecrosis. Bioact Mater. 2020; 5(3):584-601. PMC: 7210379. DOI: 10.1016/j.bioactmat.2020.04.008. View

Zhu X, Chen F, Lu K, Wei A, Jiang Q, Cao W . PPARγ preservation via promoter demethylation alleviates osteoarthritis in mice. Ann Rheum Dis. 2019; 78(10):1420-1429. DOI: 10.1136/annrheumdis-2018-214940. View

Xie H, Cui Z, Wang L, Xia Z, Hu Y, Xian L . PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med. 2014; 20(11):1270-8. PMC: 4224644. DOI: 10.1038/nm.3668. View

Tao H, Okamoto M, Nishikawa M, Yoshikawa H, Myoui A . P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption. PLoS One. 2011; 6(8):e23199. PMC: 3160289. DOI: 10.1371/journal.pone.0023199. View

Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J, Fahmi H . Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2010; 7(1):33-42. DOI: 10.1038/nrrheum.2010.196. View

Melcarne L, Garcia-Iglesias P, Calvet X . Management of NSAID-associated peptic ulcer disease. Expert Rev Gastroenterol Hepatol. 2016; 10(6):723-33. DOI: 10.1586/17474124.2016.1142872. View

McAlindon T, Bannuru R, Sullivan M, Arden N, Berenbaum F, Bierma-Zeinstra S . OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014; 22(3):363-88. DOI: 10.1016/j.joca.2014.01.003. View

Liu M, Zhong S, Kong R, Shao H, Wang C, Piao H . Paeonol alleviates interleukin-1β-induced inflammatory responses in chondrocytes during osteoarthritis. Biomed Pharmacother. 2017; 95:914-921. DOI: 10.1016/j.biopha.2017.09.011. View

10.

Herrero-Beaumont G, Roman-Blas J . Osteoarthritis: Osteoporotic OA: a reasonable target for bone-acting agents. Nat Rev Rheumatol. 2013; 9(8):448-50. DOI: 10.1038/nrrheum.2013.113. View

11.

Qiao H, Wang T, Yu Z, Han X, Liu X, Wang Y . Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model. Cell Death Dis. 2016; 7:e2094. PMC: 4849151. DOI: 10.1038/cddis.2016.11. View

12.

Zhao C, Liu Q, Wang K . Artesunate attenuates ACLT-induced osteoarthritis by suppressing osteoclastogenesis and aberrant angiogenesis. Biomed Pharmacother. 2017; 96:410-416. DOI: 10.1016/j.biopha.2017.10.018. View

13.

Song I, Kim J, Kim K, Jin H, Youn B, Kim N . Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett. 2009; 583(14):2435-40. DOI: 10.1016/j.febslet.2009.06.047. View

14.

Cui Z, Crane J, Xie H, Jin X, Zhen G, Li C . Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis. 2015; 75(9):1714-21. PMC: 5013081. DOI: 10.1136/annrheumdis-2015-207923. View

15.

Pritzker K, Gay S, Jimenez S, Ostergaard K, Pelletier J, Revell P . Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage. 2005; 14(1):13-29. DOI: 10.1016/j.joca.2005.07.014. View

16.

Munteanu I, Apetrei C . Analytical Methods Used in Determining Antioxidant Activity: A Review. Int J Mol Sci. 2021; 22(7). PMC: 8037236. DOI: 10.3390/ijms22073380. View

17.

Sniekers Y, Intema F, Lafeber F, van Osch G, van Leeuwen J, Weinans H . A role for subchondral bone changes in the process of osteoarthritis; a micro-CT study of two canine models. BMC Musculoskelet Disord. 2008; 9:20. PMC: 2259345. DOI: 10.1186/1471-2474-9-20. View

18.

Wu D, Zhou J, Creyer M, Yim W, Chen Z, Messersmith P . Phenolic-enabled nanotechnology: versatile particle engineering for biomedicine. Chem Soc Rev. 2021; 50(7):4432-4483. PMC: 8106539. DOI: 10.1039/d0cs00908c. View

19.

Han J, Gao W, Su D, Liu Y . Gypenoside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB, AKT, and MAPK signaling pathways. J Cell Biochem. 2018; 119(9):7310-7318. DOI: 10.1002/jcb.27028. View

20.

Zhao H, Zeng Z, Liu L, Chen J, Zhou H, Huang L . Polydopamine nanoparticles for the treatment of acute inflammation-induced injury. Nanoscale. 2018; 10(15):6981-6991. DOI: 10.1039/c8nr00838h. View